SARS-CoV-2 (2019-nCoV) and Related Products (SARS, MERS, Coronavirus HKU and etc. See link below):
SARS-CoV-2 (2019-nCoV) Products:
IT-002-030p: Recombinant Spike Protein S1 of Novel Coronavirus SARS-CoV-2 (CoVID-19/Wuhan), mammalian expression
IT-002-031p: Recombinant Spike Protein RBD Domain of Novel Coronavirus SARS-CoV-2 (CoVID-19/Wuhan), mammalian expression
IT-002-031p-CA: Spike RBD (CoVID-19/California mutant)
IT-002-031p-UK: Spike RBD (CoVID-19/UK mutant)
IT-002-031p-SA: Spike RBD (CoVID-19/South Africa mutant)
IT-002-031p-BR : Spike RBD (CoVID-19/Brazil mutant)
IT-002-031p-IN2: Spike RBD (CoVID-19/ Lineage B.1.617 mutant)
IT-002-032p: Recombinant Spike Protein of Novel Coronavirus (SARS-CoV-2/Wuhan/2019), Trimeric, mammalian expression
IT:-002-032p-UK: Recombinant Spike Protein (SARS-CoV-2/UK mutant), Trimeric
IT-002-032VGp: Spike Protein (A222V+D614G)(SARS-CoV-2/Wuhan/2019), Trimeric
IT-002-032p-SA: Recombinant Spike Protein (SARS-CoV-2/South Africa mutant), Trimeric
IT-002-032p-BR: Recombinant Spike Protein (SARS-CoV-2/Brazil mutant), Trimeric
IT-002-032p-NY: Recombinant Spike Protein (SARS-CoV-2/New York mutant), Trimeric
IT-002-032p-IN2: Recombinant Spike Protein (SARS-CoV-2/ Lineage B.1.617 mutant), Trimeric
IT-002-032p-CA:Recombinant Spike Protein (SARS-CoV-2/California mutant), Trimeric
IT-002-033Ep: Recombinant Nucleocapsid Protein of Novel Coronavirus SARS-CoV-2 (CoVID-19/Wuhan)
IT-002-034p: S2 Protein (SARS-CoV-2/Wuhan/2019)
IT-002-035p: Recombinant protein of Human ACE2 / Angiotensin-converting enzyme 2, mammalian expression
IT-002-036p: Recombinant Spike protein RBD Domain of Novel Coronavirus SARS-CoV-2 (CoVID-19/Wuhan), His-tagged, mammalian expression
IT-002-038p: Recombinant Spike protein NTD of Novel Coronavirus(CoVID-19/Wuhan), Fc-His-tagged,mammalian expression
IT-002-039p: Recombinant Spike protein NTD of Novel Coronavirus(CoVID-19/Wuhan), His-tagged, mammalian expression
IT-002-040p: Recombinant Spike Protein (D614G) of Coronavirus SARS-CoV-2 (SARS-CoV-2/Wuhan/2019), Trimeric, mammalian expression
IT-002-037Ep: Recombinant 3C-like proteinase of Novel Coronavirus (CoVID-19/Wuhan), His-tagged
IT-002-043Ep: Envelope (SARS-CoV-2/Wuhan/2019)
IT-002-030: Anti-Spike Protein of SARS-CoV-2 (CoVID-19/Wuhan)
IT-002-033: Anti- Nucleocapsid Protein of SARS-CoV-2(CoVID-19/Wuhan)
IT-002-031M1: Anti-Spike RBD Domain of SARS-CoV-2 (CoVID-19/Wuhan)
IT-002-031M2: Anti-Spike RBD (CoVID-19/Wuhan)
IT-002-031M3:Anti-Spike RBD (CoVID-19/Wuhan)
IT-002-031M4: Anti-Spike RBD (CoVID-19/Wuhan)
IT-002-033M1: Anti- Nucleocapsid Protein of SARS-CoV-2 (CoVID-19/Wuhan)
IT-002-032: Anti-Spike Protein of SARS-CoV-2 (CoVID-19/Wuhan)
IT-002-030SN: Anti- Spike & NP protein of SARS-CoV-2(CoVID-19/Wuhan)
IT-002-039M1: Anti- Spike NTD protein of SARS-CoV-2(CoVID-19/Wuhan)
IT-002-031M7: Anti- Spike RBD (CoVID-19/Wuhan)
IT-002-031M8: Anti- Spike RBD (CoVID-19/Wuhan)
IT-002-031M9: Anti- Spike RBD (CoVID-19/Wuhan)
IT-002-031M10; Anti- Spike RBD (CoVID-19/Wuhan)
IT-002-031M11: Anti- Spike RBD (CoVID-19/Wuhan)
Since December 2019, emerging of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has resulted in a worldwide epidemic of COVID-19, officially named by WHO for Coronavirus Disease 2019 caused by the novel coronavirus. To date, over seventy thousand people have been confirmed to be infected with SARS-CoV-2 and among them, over two thousand death have been attributed to SARS-CoV-2 infection, with vast majority of which in Wuhan, China.
Clinical progression of COVID-19 appears to be similar to that of SARS, that patients developed pneumonia around the end of the first week to the beginning of the second week of illness. However, unlike SARS, a broader spectrum of disease severity of COVID-19 has been reported, ranging from asymptomatic to mildly symptomatic to severe illness that requires mechanical ventilation. In addition, rapid disease progression has been observed in some patients. In some patients, it takes only a few hours for an asymptomatic patient to become unable to walk. Patients with severe disease are typically marked by respiratory failure, septic shock, and multi-organ failure possibly due to cytokine storm syndrome.
SARS-CoV-2 epidemic has presented major challenges for the containment of the disease. Currently, scientists have limited knowledge about the origin of virus, where the virus is replicated in human, and how it causes disease. In addition, the immune response following SARS-CoV-2 infection in patients may be quite different from other viral infection in humans. All these become major hurdles for the discovery and development of effective anti-viral drug or vaccines against SARS-CoV-2 infection. Furthermore, accumulating evidence has suggested a strong possibility that an asymptomatic individual infected with SARS-CoV-2 can transmit the virus while the mode of virus transmission between human has yet to be fully elucidated.
All of these, point to the urgent need for developing fast and reliable tools for screening, diagnosis, and theranosis of the disease. Currently, body temperature measurement, nucleic acid- based RT-PCR assay, and chest CT have been used in clinics. There is a pressing demand of immunoassay-based tools for the detection of SARS-CoV-2 antigens and antibodies in human.
Upon acquiring SARS-CoV-2 sequence in public domain, scientist at Immune Tech have geared up in developing reagents which will facilitate the development of tools for SARS-CoV-2 detection. Using our platform technology in expressing recombinant proteins, we have produced two SARS-CoV-2 related proteins, Spike Protein S1 from Coronavirus SARS-CoV-2 (CoVID-19/Wuhan) (SKU: IT-002-030p) and Spike Protein RBD Domain from Coronavirus SARS-CoV-2 (CoVID-19/Wuhan) (SKU: IT-002-031p). These two products are derived from the Spike protein of SARS-CoV-2, the surface antigen where a large number of antigenic determinants (epitopes) are present. In addition, these products are produced in mammalian cells, and there is a highly likelihood that the expressed proteins preserve a majority of epitopes (linear as well as conformation dependent), an advantageous feature over bacteria E.coli expressed recombinant proteins.
Using our proprietary GInerator™ genetic immunization platform, which combines the advantages of DNA immunization and heterologous prime-boost approach, we have generated rabbit polyclonal and mouse monoclonal antibodies against SARS-CoV-2 spike protein. Initial assay results indicate that these antibodies react with expressed recombinant proteins derived from SARS-CoV-2 spike protein. Currently we are collaborating with other institutions to define the reactivity of these antibodies to SARS-CoV-2.
While we continue to expand our SARS-CoV-2 products, we look forward to your comments and feedback about how we can better serve your research needs. If you have a particular interest in producing a specific SARS-CoV-2 protein and generating specific antibodies, please don’t hesitate to contact us.
Spike glycoprotein of coronaviruse; 2019 novel coronavirus; COVID-2019; SARS-CoV-2; 2019-nCoV; CoV Spike protein; Recombinant COVID-19 Spike protein; Severe acute respiratory syndrome coronavirus 2; novel coronavirus S protein, 2019-nCoV; NCP-CoV S protein; Spike S protein; nCoV S protein; 2019-nCoV S protein; SARS-CoV-2 S protein; novel coronavirus S1 protein, 2019-nCoV; NCP-CoV S1 protein; Spike S1 protein; nCoV S1 protein; 2019-nCoV S1 protein; SARS-CoV-2 S1 protein; novel coronavirus S2 protein, 2019-nCoV; NCP-CoV S2 protein; Spike S2 protein; nCoV S2 protein; 2019-nCoV S2 protein; SARS-CoV-2 S2 protein; novel coronavirus RBD protein, 2019-nCoV; NCP-CoV RBD protein; Spike RBD protein; nCoV RBD protein; 2019-nCoV RBD protein; SARS-CoV-2 RBD protein; novel coronavirus Nucleocapsid Protein, 2019-nCoV; NCP-CoV Nucleocapsid Protein; Nucleocapsid Protein, NP 2019-nCoV; nCoV Nucleocapsid Protein; 2019-nCoV Nucleocapsid Protein; SARS-CoV-2 Nucleocapsid Protein; Anti-coronavirus spike Antibody; Anti-coronavirus RBD Antibody; angiotensin-converting enzyme-2, ACE2; coronavirus receptor, ACE2